Johnson & Johnson: Strong Dividend Record and Diversified Business
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: Fool
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 241.300
Low
190.00
Averages
218.50
High
240.00
Current: 241.300
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
Morgan Stanley and Citizens Financial Group Earnings Outlook
- Earnings Season Kickoff: The first-quarter earnings season begins next week with 28 companies in the S&P 500 set to report, and both Morgan Stanley and Citizens Financial Group are expected to exceed Wall Street's expectations, potentially driving their stock prices higher.
- Morgan Stanley Performance: Historically, Morgan Stanley has topped analysts' earnings estimates 80% of the time, with an average post-earnings gain of 1%, indicating strong market performance and investor confidence.
- Citizens Financial Group Outlook: Citizens Financial Group has also excelled in beating earnings expectations, achieving this 80% of the time, with an average stock price increase of 1.5% following earnings releases, reflecting its solid growth potential.
- Analyst Rating Upgrade: UBS upgraded Morgan Stanley's rating from neutral to buy, raising the price target to $196, implying an approximately 11% upside, which demonstrates market confidence in quality stocks amidst recent market volatility.
See More
Southern Co. Approaches Dividend Aristocrats Eligibility
- Dividend Aristocrats Eligibility: Southern Co. is nearing eligibility for the Dividend Aristocrats index, indicating its stability and reliability in consistent dividend payments, which attracts income-focused investors.
- Steady Earnings Growth: The company has achieved steady earnings growth, which is expected to enhance its market appeal, especially as demand for stable income rises in the current economic climate.
- Attractive Yield: With a current dividend yield of 3%, Southern Co. stands out in the low-interest-rate environment, potentially drawing more income-oriented investors looking for reliable returns.
- Potential Returns: As the company approaches Dividend Aristocrats status, it is anticipated to drive its stock price higher, providing substantial returns for investors and further solidifying its leadership position in the utility sector.
See More
Pharmaceutical Industry Automation Transformation Accelerates
- Regulatory Upgrades: The EU's updated GMP Annex 1 emphasizes minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to assess and mitigate risks across personnel, processes, and environments, thus driving the pharmaceutical industry towards higher compliance standards.
- Intelligent Robotics Application: Nightfood Holdings is advancing AI-driven robotic platforms through TechForce Robotics, combining autonomous functionality with SOP intelligence and real-time deviation detection, aimed at enhancing compliance and operational efficiency in the pharmaceutical sector, reflecting the growing demand for intelligent systems in the industry.
- Persistent Contamination Risks: Despite technological advancements, FDA inspection findings indicate that deficiencies in contamination control and data integrity remain widespread, suggesting that traditional automation approaches have not fully addressed these issues, impacting drug supply chains and patient access to critical medications.
- Market Opportunities Emerge: The pharmaceutical manufacturing sector has been relatively slow to adopt automation, presenting significant market opportunities for technological advancement; Nightfood Holdings' strategic collaboration with Oncotelic Therapeutics aims to develop a GMP-compliant robotics platform, driving the industry's digital transformation.
See More
Major Leadership Change Expected at PhRMA
- Leadership Change: Stephen Ubl, the long-time president and CEO of PhRMA, is expected to resign months before his contract ends, which may impact the organization's strategic direction and industry influence.
- Tenure Context: Ubl has led PhRMA since September 2025 after over a decade at AdvaMed, and his resignation may be linked to recent drug pricing deals made by the Trump administration, reflecting shifts in both internal and external pressures within the industry.
- Political Implications: His departure comes just ahead of the U.S. midterm elections, which could significantly affect PhRMA's influence on drug policy and industry positions, especially as drug pricing issues gain prominence during the election cycle.
- Industry Reaction: PhRMA has not yet responded to Ubl's resignation, and the industry's reaction remains unclear, but it may spark widespread discussion on how new leadership will address current drug policy challenges.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
Morgan Stanley and Citizens Financial Group Earnings Outlook
- Earnings Season Kickoff: The first-quarter earnings season begins next week with 28 companies in the S&P 500 set to report, and both Morgan Stanley and Citizens Financial Group are expected to exceed Wall Street's expectations, potentially driving their stock prices higher.
- Morgan Stanley Performance: Historically, Morgan Stanley has topped analysts' earnings estimates 80% of the time, with an average post-earnings gain of 1%, indicating strong market performance and investor confidence.
- Citizens Financial Group Outlook: Citizens Financial Group has also excelled in beating earnings expectations, achieving this 80% of the time, with an average stock price increase of 1.5% following earnings releases, reflecting its solid growth potential.
- Analyst Rating Upgrade: UBS upgraded Morgan Stanley's rating from neutral to buy, raising the price target to $196, implying an approximately 11% upside, which demonstrates market confidence in quality stocks amidst recent market volatility.
See More
Southern Co. Approaches Dividend Aristocrats Eligibility
- Dividend Aristocrats Eligibility: Southern Co. is nearing eligibility for the Dividend Aristocrats index, indicating its stability and reliability in consistent dividend payments, which attracts income-focused investors.
- Steady Earnings Growth: The company has achieved steady earnings growth, which is expected to enhance its market appeal, especially as demand for stable income rises in the current economic climate.
- Attractive Yield: With a current dividend yield of 3%, Southern Co. stands out in the low-interest-rate environment, potentially drawing more income-oriented investors looking for reliable returns.
- Potential Returns: As the company approaches Dividend Aristocrats status, it is anticipated to drive its stock price higher, providing substantial returns for investors and further solidifying its leadership position in the utility sector.
See More
Pharmaceutical Industry Automation Transformation Accelerates
- Regulatory Upgrades: The EU's updated GMP Annex 1 emphasizes minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to assess and mitigate risks across personnel, processes, and environments, thus driving the pharmaceutical industry towards higher compliance standards.
- Intelligent Robotics Application: Nightfood Holdings is advancing AI-driven robotic platforms through TechForce Robotics, combining autonomous functionality with SOP intelligence and real-time deviation detection, aimed at enhancing compliance and operational efficiency in the pharmaceutical sector, reflecting the growing demand for intelligent systems in the industry.
- Persistent Contamination Risks: Despite technological advancements, FDA inspection findings indicate that deficiencies in contamination control and data integrity remain widespread, suggesting that traditional automation approaches have not fully addressed these issues, impacting drug supply chains and patient access to critical medications.
- Market Opportunities Emerge: The pharmaceutical manufacturing sector has been relatively slow to adopt automation, presenting significant market opportunities for technological advancement; Nightfood Holdings' strategic collaboration with Oncotelic Therapeutics aims to develop a GMP-compliant robotics platform, driving the industry's digital transformation.
See More
Major Leadership Change Expected at PhRMA
- Leadership Change: Stephen Ubl, the long-time president and CEO of PhRMA, is expected to resign months before his contract ends, which may impact the organization's strategic direction and industry influence.
- Tenure Context: Ubl has led PhRMA since September 2025 after over a decade at AdvaMed, and his resignation may be linked to recent drug pricing deals made by the Trump administration, reflecting shifts in both internal and external pressures within the industry.
- Political Implications: His departure comes just ahead of the U.S. midterm elections, which could significantly affect PhRMA's influence on drug policy and industry positions, especially as drug pricing issues gain prominence during the election cycle.
- Industry Reaction: PhRMA has not yet responded to Ubl's resignation, and the industry's reaction remains unclear, but it may spark widespread discussion on how new leadership will address current drug policy challenges.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
